Pluristem Therapeutics issues letter to shareholders
November 22, 2011 by stephenkilmer · Leave a Comment
Zami Aberman
In a letter to shareholders issued today, Pluristem Therapeutics (NASDAQ:PSTI; TASE:PLTR) CEO Zami Aberman reviews the company’s accomplishments over the last 12 months and outlines its challenges and opportunities in 2012 and beyond, including its Phase 1 CLI study data, out-licensing agreement with United Therapeutics (NASDAQ:UTHR) and construction of its manufacturing facility.
The full text of the letter to shareholders may be accessed here.
Listen to BioTuesdays 
